Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
On May 5, 2017, Alnylam Pharmaceuticals, Inc. (the Company)
announced its financial results for the quarter ended March 31,
2017. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
Item 5.07. Submission of Matters to a Vote of Security
Holders.
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
the Company was held on May 2, 2017. As of March 10, 2017, the
record date for the Annual Meeting, 86,052,558 shares of the
Companys common stock were issued and outstanding. A summary of
the matters voted upon by stockholders at the Annual Meeting is
set forth below.
1. The Companys stockholders re-elected the four persons listed
below as Class I directors, each to serve until the Companys 2020
annual meeting of stockholders and until his successor is duly
elected and qualified. The voting results were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |
| Michael W. Bonney | 72,449,044 | 1,013,752 | 31,532 | 5,404,213 |
| John M. Maraganore, Ph.D. | 72,672,900 | 788,748 | 32,680 | 5,404,213 |
| Paul R. Schimmel, Ph.D. | 73,153,864 | 308,969 | 31,495 | 5,404,213 |
| Phillip A. Sharp, Ph.D. | 66,585,685 | 6,877,420 | 31,223 | 5,404,213 |
The terms of office of the following directors continued after
the Annual Meeting:
|
Dennis A. Ausiello, M.D.
John K. Clarke |
|
Marsha H. Fanucci
Steven M. Paul, M.D. |
|
David E.I. Pyott
Amy W. Schulman Kevin P. Starr |
2. The Companys stockholders approved the Companys Second Amended
and Restated 2009 Stock Incentive Plan. The voting results were
as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 60,522,057 | 12,949,965 | 22,306 | 5,404,213 |
3. The Companys stockholders approved the Companys Amended and
Restated 2004 Employee Stock Purchase Plan. The voting results
were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 73,263,897 | 129,523 | 100,908 | 5,404,213 |
4. The Companys stockholders approved, in a non-binding advisory
vote, the compensation of the Companys named executive officers.
The voting results were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 72,928,360 | 430,522 | 135,446 | 5,404,213 |
5. The Companys stockholders recommended, in a non-binding
advisory vote, a frequency of every One Year for future advisory
stockholder votes on the compensation of the Companys named
executive officers. The voting results were as follows:
| One Year | Two Years | Three Years | Abstentions | Broker Non-Votes |
| 70,891,792 | 305,069 | 2,262,394 | 35,073 | 5,404,213 |
The Company currently intends to hold an advisory vote on the
compensation of its named executive officers every year until the
next required advisory vote on the frequency of holding the
advisory vote on named executive officer compensation.
6. The Companys stockholders ratified the appointment by the
Companys Board of Directors of PricewaterhouseCoopers LLP as the
Companys independent auditors for the fiscal year ending December
31, 2017. The voting results were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 78,669,571 | 204,138 | 24,832 | 0 |
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
99.1 Press Release dated May 5, 2017.
About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Recent Trading Information
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed its last trading session down -0.13 at 54.87 with 725,200 shares trading hands.
